GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Frequency Therapeutics Inc (NAS:FREQ) » Definitions » EV-to-EBITDA

Frequency Therapeutics (Frequency Therapeutics) EV-to-EBITDA : 0.12 (As of Apr. 26, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Frequency Therapeutics EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Frequency Therapeutics's enterprise value is $-7.73 Mil. Frequency Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was $-63.53 Mil. Therefore, Frequency Therapeutics's EV-to-EBITDA for today is 0.12.

The historical rank and industry rank for Frequency Therapeutics's EV-to-EBITDA or its related term are showing as below:

FREQ' s EV-to-EBITDA Range Over the Past 10 Years
Min: -66.57   Med: -1.84   Max: 0.76
Current: 0.12

During the past 6 years, the highest EV-to-EBITDA of Frequency Therapeutics was 0.76. The lowest was -66.57. And the median was -1.84.

FREQ's EV-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 9.14 vs FREQ: 0.12

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-26), Frequency Therapeutics's stock price is $0.2996. Frequency Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-1.890. Therefore, Frequency Therapeutics's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Frequency Therapeutics EV-to-EBITDA Historical Data

The historical data trend for Frequency Therapeutics's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Frequency Therapeutics EV-to-EBITDA Chart

Frequency Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBITDA
Get a 7-Day Free Trial - -16.28 -40.40 -1.14 -1.23

Frequency Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.16 -0.10 -1.23 0.12 0.10

Competitive Comparison of Frequency Therapeutics's EV-to-EBITDA

For the Biotechnology subindustry, Frequency Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Frequency Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Frequency Therapeutics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Frequency Therapeutics's EV-to-EBITDA falls into.



Frequency Therapeutics EV-to-EBITDA Calculation

Frequency Therapeutics's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=-7.726/-63.531
=0.12

Frequency Therapeutics's current Enterprise Value is $-7.73 Mil.
Frequency Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-63.53 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Frequency Therapeutics  (NAS:FREQ) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Frequency Therapeutics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.2996/-1.890
=At Loss

Frequency Therapeutics's share price for today is $0.2996.
Frequency Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.890.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Frequency Therapeutics EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Frequency Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Frequency Therapeutics (Frequency Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
75 Hayden Avenue, Suite 300, Lexington, MA, USA, 02421
Frequency Therapeutics Inc is a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused by degenerative diseases. Its Progenitor Cell Activation approach uses combinations of molecules to activate progenitor cells within the body to create functional tissue. Its product candidate FX-322 is being developed for treating sensorineural hearing loss.
Executives
Richard J. Mitrano officer: VP Finance & Operations C/O FREQUENCY THERAPEUTICS, INC., 19 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801
David L. Lucchino director, officer: President and CEO C/O FREQUENCY THERAPEUTICS, INC., 19 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801
Christopher R. Loose officer: Chief Scientific Officer C/O FREQUENCY THERAPEUTICS, INC., 19 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801
Quentin Mccubbin officer: Chief Manufacturing Officer C/O FREQUENCY THERAPEUTICS, INC., 10 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801
Wendy S Arnold officer: Chief People Officer 19 PRESIDENTIAL WAY, SUITE 203, WOBURN MA 01801
Carl Lebel officer: Chief Development Officer 23256 MARIPOSA DE ORO, MALIBU CA 90265
Peter P. Pfreundschuh officer: Chief Financial Officer C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Michael Bookman officer: General Counsel and Secretary C/O FREQUENCY THERAPEUTICS, INC., 10 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801
Joel S Marcus director, 10 percent owner C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 26 NORTH EUCLID AVENUE, PASADENA CA 91101
Cynthia L Feldmann director 17 WINTHROP ROAD, WAYLAND MA 01778
Marc A Cohen director 1000 WILSON BLVD. #1800, ARLINGTON VA 22209
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Partners, L.p. 10 percent owner, other: Possible Member of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Robert Langer director 98 MONTVALE RD, NEWTON MA 02459
Alexandria Venture Investments, Llc 10 percent owner 26 NORTH EUCLID AVENUE, PASADENA CA 91101

Frequency Therapeutics (Frequency Therapeutics) Headlines

From GuruFocus